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Melanoma Prognostics and
Personalized Therapeutics at a
Crossroad
Roger S. Lo1,2
Melanoma has recently emerged as a poster child for targeted therapies and
immunotherapies, with game-changing BRAF and immune checkpoint inhibitors
now in clinical trials and with approved clinical indications. One highly anticipated
use of novel therapeutic agents is in the adjuvant setting. Adjuvant BRAF and/or
immune checkpoint inhibition may positively affect the survival of melanoma
patients diagnosed at earlier stages but still at high risk for postsurgical relapses.
BRAF V600 mutations and, potentially, melanoma-associated immunity are pre-
dictive biomarkers for responses to these novel therapies. Emerging evidence
points to these predictive biomarkers doubling as prognostic biomarkers for high-
risk stage III patients, promising to help stratify these patients for the application
of novel adjuvant therapies.
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Inhibition of BRAF or immune checkpoint
in melanoma
Clinical exploitation of BRAF oncogene
addiction and tumor immunogenicity
in advanced melanoma has recently
culminated in the Food and Drug
Administration (FDA)’s approval of a
BRAF inhibitor (BRAFi), vemurafenib,
and an immune checkpoint inhibitor,
ipilimumab. This unprecedented success
has led to paradigm shifts in therapeutic
concepts (and in the design of clinical
trials). In the case of adenosine triphos-
phate-competitive small-molecule inhi-
bitors of mutant BRAF, success has meant
that the presence of BRAF V600 muta-
tions can predict partial (in the majority
of those treated) or complete (in a mino-
rity of those treated) melanoma shrink-
age in 50–60% of patients (Chapman
et al., 2011; Sosman et al., 2012). In
other words, the BRAF V600 mutation is
a therapeutic biomarker. Across the
board, in all melanoma patients with
BRAF V600 mutations, it is reasonable
to believe that the timing of intervention
at an advanced disease stage with overt
systemic involvement limits the initial
extent and the eventual durability of
clinical responses. Although not statisti-
cally significant, lower serum lactate
dehydrogenase before vemurafenib treat-
ment was associated with higher overall
responses (Jeffrey A. Sosman and Antoni
Ribas, personal communication). Thus,
BRAF inhibition earlier in the course of
disease may diminish the frequency of
partial initial responses and the almost
universal occurrence of acquired
(secondary) drug resistance. The mech-
anisms of BRAFi resistance are varied, but
often involve reactivation of the mitogen-
activated protein kinase (MAPK) signaling
pathway, with concomitant activation of
the RTK–PI3K–AKT signaling cascade
(Nazarian et al., 2010; Villanueva
et al., 2010; Poulikakos et al., 2011;
Wagle et al., 2011; Shi et al., 2012). On
the basis of the studies of BRAFi
resistance (Nazarian et al., 2010),
clinical trials are underway to test
combinations of targeted agents (e.g.,
against BRAF and its downstream kinase
MAPK/ERK kinase (MEK1/2) to prevent
or delay acquired BRAFi resistance.
In terms of immune checkpoint inhibi-
tors, the first success was with ipilimu-
mab, a monoclonal antibody targeting
the T-cell surface molecule called cyto-
toxic T-lymphocyte antigen 4 (CTLA-4).
CTLA-4 is a negative regulatory protein
that downregulates the priming phase
(i.e., lymph node) of antitumor immune
responses. Clinical inhibition of CTLA-4
by ipilimumab has delivered objective
response rates of about 10–15% among
metastatic melanoma patients. Although
this rate is lower than that achieved
with BRAFi, responses tend to be more
durable. In T cells, CTLA-4 competes
with the costimulatory receptor CD28
for binding to CD80 (B7-1) and CD86
(B7-2), which are expressed by antigen-
presenting cells. Other related T-cell-
negative regulatory receptors with
homology to the costimulatory CD28
receptor include program death-1 (PD-1),
B7-H4, and B- and T-lymphocyte atten-
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uator. Unlike CTLA-4, which counters
T-cell interaction with antigen-present-
ing cells during the priming stage, PD-1
counters T-cell interaction with tumor
cells during the effector stage, via inter-
action with the PD-1 ligand, PD-L1,
which is expressed by tumor cells or
the tumor microenvironment. Early clin-
ical data with other immune checkpoint
inhibitors, namely monoclonal antibod-
ies against the PD-1 receptor (Topalian
et al., 2012) and its ligand PD-L1/B7-H1
(Brahmer et al., 2012), has jolted the
melanoma field and beyond, with
20–30% objective response rates
among patients with metastatic mela-
noma, renal cell carcinoma, and even
non-small-cell lung carcinoma, which
is notoriously resistant to other immu-
notherapies. The durability of responses
in the majority of patients treated with
monoclonal antibodies against CTLA-4,
PD-1, and PD-L1 contrasts with the
shorter durabilities of responses to BRA-
Fis. However, in contrast to the deploy-
ment of BRAFis guided by detection of
BRAF V600 mutations, there is currently
no prospectively tested therapeutic
biomarker that guides the deployment
of immune checkpoint inhibitors. Emer-
ging evidence supports an immune-
active tumor microenvironment (as indi-
cated by immune gene signature,
infiltrate, or paradoxical elaboration of
negative feedback PD-L1 upregulation)
potentially correlating with improved
melanoma patient survival or response
to immune checkpoint inhibitors.
Stage III melanoma: prognostic factors
meet therapeutic biomarkers
Therapeutic biomarkers have the poten-
tial to double as prognostic and
predictive factors (Figure 1). A prognos-
tic factor offers information on the likely
course of a cancer (or any other disease)
in an untreated patient, providing infor-
mation on patient outcomes indepen-
dent of subsequent therapy. Among
low-risk or early-stage melanoma
patients, for instance, well-defined prog-
nostic factors would be helpful in select-
ing patients for adjuvant systemic
clinical trials, which, in the case of
melanoma where options are few,
should more often than not be recom-
mended. On the other hand, a predic-
tive factor offers information to stratify
subsets of patients who are more likely
to respond to a given therapy. Thus,
predictive factors imply a rational ability
to select a specific therapy, thereby
improving the anticipated outcome for
that subpopulation of patients.
Clinicopathologic features have domi-
nated as prognostic factors for primary
melanoma, with molecular features pro-
ducing less useful results. Recent data
suggest that BRAF mutations may be
associated with worse survival in stage
IV melanomas (Long et al., 2011). What
about stage III melanoma (metastasis to
lymph nodes or in-transit metastasis)? In
stage III melanoma, the 5-year and 10-
year survival varies from 80 to 40% and
from 70 to 25%, respectively, owing to
some patients being at a high risk of
recurrence and death even after surgery
for resectable cases. Currently, the only
FDA-approved adjuvant treatments for
such patients are high-dose interferon
alpha-2b and pegylated interferon.
There are few data specifically pertain-
ing to the adjuvant use of any therapy,
including interferons, for patients at the
highest recurrence risk category (stage
IIIb and c). Clinical trials are underway
to accrue high-risk patients with resected
stage IIIc/IV disease and prospectively
randomize them to high-dose interferon
versus ipilimumab. Hence, prognostic
and predictive factors for stage III mela-
noma (and specifically for stage IIIb and
c patients) would help stratify patients
further for adjuvant therapeutic trials.
It is interesting to note that in this
issue Mann et al. (2012) report on the
outcome (time from nodal resection to
death) of a group of melanoma patients
with surgically resected macroscopic
nodal metastasis (stage IIIb and IIIc).
They examined this outcome by
multivariate analysis with respect to a
detailed series of clinicopathologic
variables and molecular features (NRAS
and BRAF mutation status and expres-
sion signatures) and their association
with good versus poor prognosis groups.
The investigators hypothesized that the
conventional primary melanoma pro-
gnostic factors (Breslow’s thickness,
mitotic rate, ulceration; 2009 revised
American Joint Committee on Cancer
staging criteria), which portend eventual
metastasis, may not be similarly strong
prognostic factors once the disease has
progressed overtly to involve lymph
node metastasis. Indeed, they found
that either NRAS or BRAF mutations
(versus those wild type in both genes)
were associated independently with a
worse prognosis (survivalo1 year). In
a separate report, stage III melanoma
patients with BRAF V600 mutation have
also been shown to fare worse in terms
of overall survival compared with those
with BRAF wild type status (Moreau et al.,
2012). In addition, Mann et al. (2012)
show that a gene expression signature
comprising 46 genes and enriched for
biological pathways consistent with
immune activation independently predict
a better prognosis (survival 41 year).
Importantly, this gene signature was also
found to be associated with good prog-
nosis in two independent stage III mela-
noma data sets.
Adjuvant therapy using BRAFi and
immune checkpoint inhibitors
The first targeted therapy, trastuzumab
(which targets overexpression or ampli-
fication of the epidermal growth factor
receptor 2 or human epidermal growth
Clinical Implications
 Inhibitors of mutant BRAF and tumor-associated immune checkpoints
have shown unprecedented clinical activities against advanced melanoma.
 Clinical trials are currently testing BRAF and immune checkpoint inhibitors
in the adjuvant setting in earlier-stage patients at high risk of postsurgical
disease recurrence.
 Stratification of high-risk patients on the basis of prognostic biomarkers
that are mechanistically linked to therapeutic biomarkers may identify
those patients most receptive to adjuvant BRAF and/or immune check-
point inhibitors.
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factor receptor 2), was originally devel-
oped for advanced breast cancer, but it
has now become a standard adjuvant
therapy for human epidermal growth
factor receptor 2-positive early-stage
breast cancer. There is no reason why
BRAFi and immune checkpoint inhibitors
cannot do the same for the adjuvant
treatment of high-risk early-stage or inter-
mediate-stage melanoma. The reality of
long-term treatment (perhaps up to 1 year
or longer after surgery) and issues of drug-
related toxicities should not dissuade the
use of these highly active (and paradigm-
changing) therapies for melanoma, in
order to improve progression-free survival
or overall survival. Intervention when the
tumor burden is low, informed by prog-
nostic factors that mechanistically relate
to therapeutic biomarkers, may well be a
recipe for success.
Yes, grade 3 and grade 4 toxicities of
BRAFi’s and immune checkpoint inhibi-
tors have made headlines. For instance,
BRAFis, including vemurafenib and dab-
rafenib, accelerate the formation of cuta-
neous squamous cell carcinomas. This
has been attributed to a pharmacologic
property termed ‘‘paradoxical MAPK
pathway activation’’ in BRAF wild-type
tissues and cells harboring activation
signals upstream of RAF. In addition,
ipilimumab can lead to serious side
effects, such as colitis, presumably attri-
butable to drug-induced autoimmunity.
However, unlike drug toxicities in the
past, rational strategies to overcome drug
toxicities are becoming available. The
combination of BRAF and MEK inhibition
to prevent cutaneous squamous cell car-
cinomas (Su et al., 2012) and targeting of
alternative immune checkpoints with
higher specificity to produce antitumor
(rather than anti-host) immunity are two
successful examples.
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Figure 1. Mutant BRAF and immune response in melanoma: prognostic and predictive biomarkers. In melanoma macroscopically metastatic to lymph nodes,
disease recurrence and poor survival after complete surgical resection are associated with BRAF (and NRAS) mutations and the lack of an immune response or
signature, both of which serve as independent prognostic biomarkers for this high-risk group of patients. Prognostic biomarkers indicate the likely course of
disease without treatment after surgical resection of melanoma metastatic to a lymph node(s). The upward arrow indicates those patients who will likely relapse
after surgery. BRAF (V600E/K) mutations may serve as predictive biomarkers for adjuvant therapeutic responses to a BRAF inhibitor (BRAFi) or the combination of
a BRAFi with MAPK/ERK kinase inhibitor (both clinical trials are underway). Predictive biomarkers identify a subset of patients most likely to respond to the
indicated adjuvant therapy (right, left, and downward arrows). The presence of a tumor-associated immune response (or a more specific surrogate marker such as
PD-L1 expression) may serve as a predictive biomarker for adjuvant therapeutic response to an immune checkpoint inhibitor (ICi). The combination of BRAFi
and ICi in an adjuvant setting may benefit those patients with BRAF mutant melanomas showing evidence of tumor-associated immunity. Alternatively, according
to one hypothesis, BRAFi may induce tumor-associated immunity, thereby predicting responses to the combination of BRAFi and ICi. Red circle, BRAF (V600E/K)
melanomas; white circle, BRAF wild-type melanomas; yellow halo, melanoma-associated immunity.
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